JPS63119498A - 新規なモノクロナル抗体、その製造及び使用 - Google Patents
新規なモノクロナル抗体、その製造及び使用Info
- Publication number
- JPS63119498A JPS63119498A JP62187856A JP18785687A JPS63119498A JP S63119498 A JPS63119498 A JP S63119498A JP 62187856 A JP62187856 A JP 62187856A JP 18785687 A JP18785687 A JP 18785687A JP S63119498 A JPS63119498 A JP S63119498A
- Authority
- JP
- Japan
- Prior art keywords
- bound
- monoclonal antibody
- label
- enzyme
- acetylglucosamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 34
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 34
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims abstract description 30
- 210000002421 cell wall Anatomy 0.000 claims abstract description 11
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims abstract description 7
- 239000012620 biological material Substances 0.000 claims abstract description 6
- 238000001514 detection method Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 23
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 13
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 13
- 239000000020 Nitrocellulose Substances 0.000 claims description 13
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 13
- 229920001220 nitrocellulos Polymers 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 102000013361 fetuin Human genes 0.000 claims description 10
- 108060002885 fetuin Proteins 0.000 claims description 10
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 241000699670 Mus sp. Species 0.000 claims description 6
- 210000004408 hybridoma Anatomy 0.000 claims description 6
- 241001529936 Murinae Species 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- 108090001008 Avidin Proteins 0.000 claims description 3
- 102000005348 Neuraminidase Human genes 0.000 claims description 3
- 108010006232 Neuraminidase Proteins 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 3
- 102000002464 Galactosidases Human genes 0.000 claims description 2
- 108010093031 Galactosidases Proteins 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 101710120037 Toxin CcdB Proteins 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 5
- 238000002372 labelling Methods 0.000 claims 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 238000004040 coloring Methods 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 abstract description 15
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 208000011231 Crohn disease Diseases 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282346 Meles meles Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 2
- 206010006049 Bovine Tuberculosis Diseases 0.000 description 2
- 241000220451 Canavalia Species 0.000 description 2
- 235000010520 Canavalia ensiformis Nutrition 0.000 description 2
- 241001274613 Corvus frugilegus Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- AYXZIZMZXAORLO-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;1-hydroxypyrrolidine-2,5-dione Chemical compound ON1C(=O)CCC1=O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 AYXZIZMZXAORLO-UFLZEWODSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8618443 | 1986-07-29 | ||
| GB868618443A GB8618443D0 (en) | 1986-07-29 | 1986-07-29 | Monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63119498A true JPS63119498A (ja) | 1988-05-24 |
Family
ID=10601843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62187856A Pending JPS63119498A (ja) | 1986-07-29 | 1987-07-29 | 新規なモノクロナル抗体、その製造及び使用 |
Country Status (13)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03200064A (ja) * | 1989-12-28 | 1991-09-02 | Kosumitsuku:Kk | 悪性腫瘍に対する抗体、及びこの抗体を用いた悪性腫瘍の判別方法 |
| JP2005535723A (ja) * | 2002-08-20 | 2005-11-24 | バイオティ セラピィーズ コープ | 腫瘍特異的オリゴ糖エピトープおよびその用途 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622871A (en) | 1987-04-27 | 1997-04-22 | Unilever Patent Holdings B.V. | Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents |
| US5271927A (en) * | 1986-02-13 | 1993-12-21 | Celltech Limited | Antibody conjugates with macrocyclic ligands |
| CA1303983C (en) * | 1987-03-27 | 1992-06-23 | Robert W. Rosenstein | Solid phase assay |
| ATE195022T1 (de) | 1987-04-27 | 2000-08-15 | Unilever Nv | Spezifische bindungstestverfahren |
| US4855240A (en) * | 1987-05-13 | 1989-08-08 | Becton Dickinson And Company | Solid phase assay employing capillary flow |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8719041D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8726271D0 (en) * | 1987-11-10 | 1987-12-16 | Univ London | Protein glycosylation assay |
| US5342936A (en) * | 1989-02-10 | 1994-08-30 | David Parker | Tetra-aza macrocycles and processes for their preparation |
| US6352862B1 (en) | 1989-02-17 | 2002-03-05 | Unilever Patent Holdings B.V. | Analytical test device for imuno assays and methods of using same |
| US5247077A (en) * | 1989-06-23 | 1993-09-21 | Celltech Limited | Tri-aza macrocycles and processes for their preparation |
| WO2000061636A2 (en) * | 1999-04-14 | 2000-10-19 | Research Corporation Technologies, Inc. | Aberrantly glycosylated antibodies as marker for cancer |
| GB0002660D0 (en) * | 2000-02-04 | 2000-03-29 | Biomade B V | Method of stabilizing a hydrophobin-containing solution and a method of coatinga surface with a hydrophobin |
| IL154853A0 (en) * | 2000-10-27 | 2003-10-31 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a & b |
| FI20011671A7 (fi) | 2001-08-20 | 2003-02-21 | Carbion Oy | Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö |
| CA3215117A1 (en) | 2021-04-01 | 2022-10-06 | Becton, Dickinson And Company | Methods for enhancing specificity and sensitivity of group a streptococcus immunoassay |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3790447A (en) * | 1972-07-05 | 1974-02-05 | Abbott Lab | Streptococci diagnostic method |
| SE7712244L (sv) * | 1977-10-31 | 1979-05-01 | Jonsson U R S | Forfarande for framstellning av preparationer av avdodade bakterier |
| US4292296A (en) | 1978-09-12 | 1981-09-29 | Baxter Travenol Laboratories, Inc. | Diagnostic method |
| GB2093993A (en) | 1980-07-25 | 1982-09-08 | Otsuka Pharma Co Ltd | Method for determining tumor-associated glucose side chain method for diagnosing tumors and kit for diagnosing tumors |
| US4489167A (en) * | 1981-06-02 | 1984-12-18 | Baxter Travenol Laboratories, Inc. | Methods and compositions for cancer detection |
| EP0114818B1 (en) * | 1982-08-09 | 1987-08-12 | Centocor, Inc. | Immunoassay for carbohydrate antigenic determinant |
| EP0141818A1 (en) * | 1983-04-18 | 1985-05-22 | Quidel | Removal of self-binding and staph a cross-reactivity of anti-strep antibody |
| JPS608228A (ja) * | 1983-06-28 | 1985-01-17 | Kyowa Hakko Kogyo Co Ltd | モノクロ−ナル抗体 |
| CA1231050A (en) * | 1984-01-27 | 1988-01-05 | Joseph W. Holland | PROCEDURE FOR DETECTING .beta.-HEMOLYTIC STREPTOCOCCUS ANTIGENS |
| US4618576A (en) * | 1984-02-27 | 1986-10-21 | Becton Dickinson And Company | Diagnostic test for Streptococcus A |
| US4659659A (en) * | 1985-01-22 | 1987-04-21 | Monsanto Company | Diagnostic method for diseases having an arthritic component |
-
1986
- 1986-07-29 GB GB868618443A patent/GB8618443D0/en active Pending
-
1987
- 1987-07-28 DE DE8787306664T patent/DE3779207D1/de not_active Expired - Fee Related
- 1987-07-28 IE IE204187A patent/IE59984B1/en not_active IP Right Cessation
- 1987-07-28 ZA ZA875551A patent/ZA875551B/xx unknown
- 1987-07-28 AT AT87306664T patent/ATE76512T1/de not_active IP Right Cessation
- 1987-07-28 GB GB8717792A patent/GB2195343B/en not_active Expired - Lifetime
- 1987-07-28 AU AU76267/87A patent/AU601455B2/en not_active Ceased
- 1987-07-28 DK DK392387A patent/DK392387A/da not_active Application Discontinuation
- 1987-07-28 ES ES198787306664T patent/ES2032447T3/es not_active Expired - Lifetime
- 1987-07-28 EP EP87306664A patent/EP0255342B1/en not_active Expired - Lifetime
- 1987-07-28 NZ NZ221230A patent/NZ221230A/en unknown
- 1987-07-29 JP JP62187856A patent/JPS63119498A/ja active Pending
-
1992
- 1992-08-20 GR GR920401195T patent/GR3005450T3/el unknown
-
1993
- 1993-03-10 US US08/031,075 patent/US6391634B1/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| HOPPE-SEYLEY S Z PHYSIOL CHEM 365-12=1984 * |
| IMMUNOBIOLOGY 156 1-2=1979 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03200064A (ja) * | 1989-12-28 | 1991-09-02 | Kosumitsuku:Kk | 悪性腫瘍に対する抗体、及びこの抗体を用いた悪性腫瘍の判別方法 |
| JP2005535723A (ja) * | 2002-08-20 | 2005-11-24 | バイオティ セラピィーズ コープ | 腫瘍特異的オリゴ糖エピトープおよびその用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| GB8618443D0 (en) | 1986-09-03 |
| AU601455B2 (en) | 1990-09-13 |
| DK392387D0 (da) | 1987-07-28 |
| GB2195343B (en) | 1990-08-01 |
| GR3005450T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-05-24 |
| NZ221230A (en) | 1990-04-26 |
| DE3779207D1 (de) | 1992-06-25 |
| ATE76512T1 (de) | 1992-06-15 |
| US6391634B1 (en) | 2002-05-21 |
| IE872041L (en) | 1988-01-29 |
| GB8717792D0 (en) | 1987-09-03 |
| AU7626787A (en) | 1988-02-04 |
| ZA875551B (en) | 1988-04-27 |
| IE59984B1 (en) | 1994-05-04 |
| GB2195343A (en) | 1988-04-07 |
| EP0255342A1 (en) | 1988-02-03 |
| ES2032447T3 (es) | 1993-02-16 |
| EP0255342B1 (en) | 1992-05-20 |
| DK392387A (da) | 1988-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS63119498A (ja) | 新規なモノクロナル抗体、その製造及び使用 | |
| JP5197535B2 (ja) | リソソーム病の検出方法 | |
| US6649743B1 (en) | Monoclonal antibody against estrogen stimulated leucine aminopeptidase | |
| JP2024045646A (ja) | 抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法 | |
| KR102826926B1 (ko) | 브루가다 증후군과 관련된 바이오마커의 검출 | |
| PL177771B1 (pl) | Linie komórek hybrydoma i preparaty przeciwciał | |
| US5376531A (en) | Method of detecting cancer | |
| JP2779178B2 (ja) | 標的リガンド用アッセイの感度を高める方法 | |
| JPH08100000A (ja) | ヒトｉｖ型コラーゲンに対する抗体及びその利用 | |
| Jeanneau et al. | Use of monoclonal antibody and colloidal gold in EM localization of von Willebrand factor in megakaryocytes and platelets | |
| US6235487B1 (en) | Method of diagnosing Crohn's disease | |
| JPH11507435A (ja) | 分析および治療用薬剤 | |
| EP0782863A1 (en) | Antibody reagent for detecting dissecting aortic aneurysm and use thereof | |
| JP3749636B2 (ja) | メダラシンの免疫学的測定方法 | |
| RU2157540C2 (ru) | Способ определения или обнаружения повреждения органа-донора после ксенотрансплантации на основе анализа веществ, полученных из органа-донора | |
| JP2878317B2 (ja) | ラミニン測定試薬 | |
| US20040038295A1 (en) | Assays | |
| JPH02264864A (ja) | Ｇｓａ―２結合性蛋白質の免疫学的測定試薬及びそれを用いた免疫学測定用キット | |
| CN120504744A (zh) | 功能性片段、泛素羧基末端水解酶l1抗体及其应用 | |
| JPS62270598A (ja) | 新規な腫瘍関連抗原 | |
| CA2303505C (en) | A monoclonal antibody against estrogen stimulated leucine aminopeptidase | |
| Vengerov et al. | Immunochemical studies of human placental alkaline phosphatase in normal and neoplastic tissues | |
| EA045148B1 (ru) | Способы уменьшения мешающего влияния мишени лекарственного средства в иммунологическом анализе на антитела к лекарственному средству (ada) | |
| JPH11142404A (ja) | メニエール病特異抗原及びその医学的用途 | |
| JPH10185917A (ja) | 糖尿病もしくは糖尿病合併症用マーカーとしての使用および免疫試薬 |